Titan Pharma

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura®-based TP-2021 implant in an established animal model of chronic pruritus will be presented at the Society for Neuroscience 2021 Meeting, being held virtually, on November 8.

Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to deliver a human immunodeficiency virus ("HIV") preventative therapeutic and a contraceptive from a single implant using its proprietary ProNeura® technology, and ensure this technology is accessible to women and adolescent girls in low- and middle-income countries.

Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a research and option license agreement (the "Agreement") with the MUSC Foundation for Research Development ("MUSC FRD").

Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement

SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," formerly JT-09) ProNeura®-based implant in an established 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model, has demonstrated the potential to provide extended efficacy and durability in the treatment of moderate-to-severe chronic pruritus (itch).

Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ --  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission ("SEC").

Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K

The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is trading at over 15% pre-market. This is why it happened.

TTNP Stock Price Increases Over 15% Pre-Market: Why It Happened

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor ("KOR"). JT-09 is being developed...

Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $9.7 million of its common stock in a...

Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m....

Titan Pharmaceuticals Announces Reverse Stock Split

The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has increased by 34.75% from $0.13 per share to $0.17 per share. This is an explanation of why it happened.

TTNP Stock Price Increases 34.75%: Why It Happened

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended September 30, 2020 and provided an update on its business. Third Quarter 2020 and Recent Highlights...

Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results

Cinedigm

Dynavax Technologies

Neos Therapeutics

Nokia

Rolls-Royce Holdings PLC

Waitr Holdings Inc

Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.

7 Penny Stocks to Watch in November

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a price of $0.10 per unit. Each unit issued in the offering consists of one share of common stock and...

Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

Titan Pharmaceuticals (TTNP) is making news on Wednesday after announcing a deal with JT Pharma to acquire one of its assets. The post Titan Pharmaceuticals News: 8 Things for TTNP Stock Investors to Know about the JT Pharma Deal appeared first on InvestorPlace.

Titan Pharmaceuticals News: 8 Things for TTNP Stock Investors to Know about the JT Pharma Deal

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura® long-term, continuous drug delivery technology, today announced its...

Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders approved the proposal to amend Titan's certificate of incorporation to increase the number of...

Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2020 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals To Report Second Quarter 2020 Financial Results On August 14, 2020

SOUTH SAN FRANCISCO, Calif., July 8, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today urged its stockholders to vote "FOR" an amendment to its certificate of incorporation that will provide additional shares for potential financings as and...

Titan Pharmaceuticals Urges Stockholders to Vote "FOR" Proposal to Amend Its Certificate of Incorporation

SAN FRANCISCO, June 24, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with Indegene Inc. to establish multichannel digital marketing programs throughout the United States and...

Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership

Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2020 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the first quarter ended March 31, 2020 and provided an update on its business. First Quarter 2020 Highlights In January...

Titan Pharmaceuticals Reports First Quarter 2020 Financial Results

Alimera Sciences

Cumberland Pharma

Overseas Shipholding Group

Roadrunner Transportation

In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.

News for Titan Pharma Stock (TTNP)